Adagene (ADAG) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Good morning, everyone. Thank you for attending Jefferies Global Healthcare Conference. My name is Kelly Xu, a senior analyst on biotech team here. Please join me in the welcome mister Mikhail Chengdu, strategic adviser, IR and the BD of Atogene for this first set of chat session. Welcome. Speaker1 Thanks for having me. Speaker0 Maybe for investors not very familiar with Atogene, could you provide a overview of the company, and what do you ar ...

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science ...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for over forty weeks Median overall survival (OS) for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months and only 1 out of 41 patients was ...

- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immu ...

Core Insights - Adagene Inc. is set to present a poster at ASCO 2025, showcasing its advancements in antibody-based therapies [1][2] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [3] - The company has established strategic collaborations with global partners to enhance its SAFEbody precision masking technology [3] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, aimed at addressing safety and tolerability issues in antibody therapeutics [4] - The SAFEbody technology allows for tumor-specific targeting of antibodies while minimizing toxicity to healthy tissues [4] Clinical Programs - The lead clinical program, ADG126 (muzastotug), is an anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, focusing on Metastatic Microsatellite-stable Colorectal Cancer [5] - ADG126 targets a unique epitope of CTLA-4 in regulatory T cells within the tumor microenvironment and is being studied in combination with anti-PD-1 therapy [5] Upcoming Presentation Details - The poster presentation titled "Safety and Efficacy of ADG126 (an Anti-CTLA-4 Masking Antibody) in Combination with Pembrolizumab" will take place on May 31, 2025, at ASCO 2025 [7]

SAN DIEGO and SUZHOU, China, April 07, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Stifel's 2025 Virtual Targeted Oncology Forum, taking place April 8-9. Stifel's 2025 Virtual Targeted Oncology Forum Presentation Da ...

SAN DIEGO and SUZHOU, China, April 07, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Stifel’s 2025 Virtual Targeted Oncology Forum, taking place April 8-9. Stifel’s 2025 Virtual Targeted Oncology Forum Presentation D ...

Currency Exchange and Economic Conditions - The Renminbi depreciated approximately by 9% against the U.S. dollar in 2022, appreciated approximately by 3% in 2023, and depreciated approximately by 1% in 2024[1085]. - The Renminbi's value is influenced by China's political and economic conditions, and future changes to the exchange rate system may occur[1085]. - The company has not experienced significant direct foreign exchange risk, but the value of investments in ADSs may be affected by exchange rate fluctuations[1084]. Inflation and Consumer Price Index - Year-over-year percent changes in the consumer price index in China were an increase of 2.0% in December 2022, a decrease of 0.3% in 2023, and an increase of 0.1% in 2024[1087]. - The company anticipates that inflation in China has not materially impacted its operations since inception, but future inflation rates may pose risks[1087]. Interest Rate and Financial Instruments - The company has not been exposed to material risks due to changes in interest rates, but future interest income may be lower than expected due to market fluctuations[1083]. - The company has not used any derivative financial instruments to manage interest rate or foreign exchange risk exposure[1084]. - The company has not used any derivative financial instruments to hedge foreign exchange risk exposure[1084]. ADR Program and Fees - The company has not received reimbursement from the depositary for expenses incurred in respect of the ADR program as of the date of the annual report[1103]. - The depositary may charge fees for various transactions related to ADSs, including a fee of $5.00 for each 100 ADSs issued or surrendered[1092].

Exhibit 99.1 Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index Cash balance of $85.2 million provides runway into late 2026 SAN DIEGO, Calif. and SUZHOU, China, March 24, 2025 – Adagene Inc. ("Adag ...

Core Insights - Adagene Inc. reported a 33% overall response rate in its Phase 2 dose expansion study for ADG126 in microsatellite stable colorectal cancer (MSS CRC) with a 20 mg/kg loading dose regimen, including four confirmed partial responses [1][4] - The company has a cash balance of $85.2 million, which is expected to fund operations into late 2026 [1][9] - Adagene's SAFEbody technology is designed to enhance the safety profile and therapeutic index of antibody-based therapies, particularly in the context of immunotherapy [1][25] Clinical Development - ADG126, a masked anti-CTLA-4 SAFEbody, is currently in Phase 1b/2 clinical studies in combination with pembrolizumab for MSS CRC [26] - The company plans to expand its study to include earlier lines of therapy and patients with liver metastases, who have historically benefited little from checkpoint inhibitors [2][4] - The combination of ADG126 with T cell engagers (TCEs) is expected to enhance therapeutic responses by depleting regulatory T cells [2] Financial Performance - For the year ended December 31, 2024, Adagene reported a net revenue of $0.1 million, a significant decrease from $18.1 million in 2023 [14] - Research and development expenses decreased by approximately 21% to $28.8 million in 2024, reflecting a focus on ADG126 [15] - The net loss attributable to shareholders was $33.4 million for 2024, compared to $18.9 million in 2023 [18] Collaborations and Partnerships - Adagene has ongoing collaborations with Exelixis, Sanofi, and Roche, focusing on the development of SAFEbody technology and other therapeutic candidates [6][7][8] - The collaboration with Exelixis has resulted in milestone payments totaling over $18 million to date [6] - The partnership with Sanofi includes potential milestone payments of up to $2.5 billion and tiered royalties [7] Future Milestones - The company expects to conduct an End-of-Phase 1 meeting with the FDA by Q3 2025 to discuss proposed dosing regimens and trial designs [12] - Initial clinical data from an investigator-initiated Phase 2 trial for neoadjuvant ADG126 in colorectal cancer is anticipated [12] - Adagene aims to establish additional collaboration and licensing agreements in the near future [12]